{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:32:38Z","timestamp":1790865158082,"version":"4.1.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,12,15]]},"DOI":"10.2169\/internalmedicine.0241-22","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T22:15:36Z","timestamp":1664316936000},"page":"3703-3708","source":"Crossref","is-referenced-by-count":4,"title":["Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies"],"prefix":"10.2169","volume":"61","author":[{"given":"Akihiro","family":"Shimizu","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Shirai","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Haruhara","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Oshiro","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yokote","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Katsushika Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okabe","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Daisan Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ueda","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 222: 1103-1107, 2020.","DOI":"10.1093\/infdis\/jiaa446"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother 27: 387-389, 2021.","DOI":"10.1016\/j.jiac.2020.12.001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell-depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin Infect Dis 73: e4020-4024, 2021.","DOI":"10.1093\/cid\/ciaa1637"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Reuken PA, Stallmach A, Pletz MW, et al. Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection. Leukemia 35: 920-923, 2021.","DOI":"10.1038\/s41375-021-01175-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Levi G, Rocchetti C, Magri R, et al. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Arch Chest Dis 91: 1867, 2021.","DOI":"10.4081\/monaldi.2021.1867"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Luitel P, Vais D, Gidron A. Successful treatment of persistent coronavirus disease 2019 infection in a patient with hypogammaglobulinemia with REGN-COV2: a case report. Open Forum Infect Dis 8: ofab335, 2021.","DOI":"10.1093\/ofid\/ofab335"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zimmerli A, Monti M, Fenwick C, et al. Case report: stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma therapy with full clinical recovery. Front Immunol 12: 613502, 2021.","DOI":"10.3389\/fimmu.2021.613502"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Horiuchi H, Sasaki H, Miyazaki K, et al. Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab. J Infect Chemother 28: 329-332, 2022.","DOI":"10.1016\/j.jiac.2021.11.018"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Daher A, M\u00fcller T, Spiesshoefer J, et al. Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-cell aplasia due to treatment with an anti-CD20 monoclonal antibody: a case report. Respir Med Case Rep 34: 101560, 2021.","DOI":"10.1016\/j.rmcr.2021.101560"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Arai T, Mukai S, Kazama R, et al. Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: a case report. J Infect Chemother 28: 810-813, 2022.","DOI":"10.1016\/j.jiac.2022.01.014"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Deveci B, Saba R. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: case reports. Medicine (Baltimore) 100: e28470, 2021.","DOI":"10.1097\/MD.0000000000028470"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Taha Y, Wardle H, Evans AB, et al. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob 20: 85, 2021.","DOI":"10.1186\/s12941-021-00491-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Elcioglu OC, Artan AS, Mirioglu S, et al. COVID-19 infection in a membranous nephropathy patient treated with rituximab. CEN Case Rep 10: 83-87, 2021.","DOI":"10.1007\/s13730-020-00524-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Paybast S, Shahrab F, Hejazi SA. Recurrence of COVID-19 in a patient with NMO spectrum disorder while treating with rituximab: a case report and review of the literature. Neurologist 26: 281-283, 2021.","DOI":"10.1097\/NRL.0000000000000371"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Caba\u00f1ero-Navalon MD, Garcia-Bustos V, Ruiz-Rodriguez P, et al. Persistent SARS-CoV-2 infection with repeated clinical recurrence in a patient with common variable immunodeficiency. Clin Microbiol Infect 28: 308-310, 2022.","DOI":"10.1016\/j.cmi.2021.10.021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nguyen H, Salkeld J, Agarwal S, Goodman A. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. Clin Infect Pract 12: 100089, 2021.","DOI":"10.1016\/j.clinpr.2021.100089"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Guitard J, Hebral AL, Fakhouri F, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant 29: 2084-2091, 2014.","DOI":"10.1093\/ndt\/gfu209"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25: 850-863, 2014.","DOI":"10.1681\/ASN.2013030251"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 83: 511-516, 2013.","DOI":"10.1038\/ki.2012.444"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore) 93: e300, 2014.","DOI":"10.1097\/MD.0000000000000300"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kobayashi M, Kageyama Y, Ando T, et al. All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome. Clin Exp Nephrol 25: 854-864, 2021.","DOI":"10.1007\/s10157-021-02035-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yusof MY, Vital EM, McElvenny DM, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 71: 1812-1823, 2019.","DOI":"10.1002\/art.40937"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33: 388-396, 2013.","DOI":"10.1007\/s10875-012-9813-x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Demoulin N, Scohy A, Gillion V, et al. Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab. Clin Kidney J 14: 2132-2133, 2021.","DOI":"10.1093\/ckj\/sfab102"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol 74: e21-e36, 2022.","DOI":"10.1002\/art.42109"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kronbichler A, Anders HJ, Fernandez-Ju\u00e1rez GM, et al. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrol Dial Transplant 36: 1160-1168, 2021.","DOI":"10.1093\/ndt\/gfab064"},{"key":"27","unstructured":"27. Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80: 930-942, 2021."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Langer-Gould A, Smith JB, Li BH. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol 8: 938-943, 2021.","DOI":"10.1002\/acn3.51342"},{"key":"29","unstructured":"29. RECOVERY Collaborative Groupe. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399: 665-676, 2022."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Stein D, Oviedo-Orta E, Kampman WA, et al. Compassionate use of REGEN-COV<sup>\u00ae<\/sup> in patients with coronavirus disease 2019 (COVID-19) and immunodeficiency-associated antibody disorders. Clin Infect Dis e509-e515, 2021.","DOI":"10.1093\/cid\/ciab1059"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/24\/61_0241-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T03:23:13Z","timestamp":1671247393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/24\/61_0241-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0241-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"0241-22"}}